NTBL vs. ONCO, SNOA, SXTP, SLRX, AGRX, CYTO, ATXI, DRMA, VRPX, and CMND
Should you be buying Notable Labs stock or one of its competitors? The main competitors of Notable Labs include Onconetix (ONCO), Sonoma Pharmaceuticals (SNOA), 60 Degrees Pharmaceuticals (SXTP), Salarius Pharmaceuticals (SLRX), Agile Therapeutics (AGRX), Altamira Therapeutics (CYTO), Avenue Therapeutics (ATXI), Dermata Therapeutics (DRMA), Virpax Pharmaceuticals (VRPX), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical preparations" industry.
Onconetix (NASDAQ:ONCO) and Notable Labs (NASDAQ:NTBL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Onconetix has a beta of 3.34, meaning that its stock price is 234% more volatile than the S&P 500. Comparatively, Notable Labs has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
23.9% of Onconetix shares are held by institutional investors. Comparatively, 70.5% of Notable Labs shares are held by institutional investors. 19.5% of Onconetix shares are held by insiders. Comparatively, 1.2% of Notable Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Notable Labs received 6 more outperform votes than Onconetix when rated by MarketBeat users.
Onconetix's return on equity of -62.07% beat Notable Labs' return on equity.
In the previous week, Notable Labs had 4 more articles in the media than Onconetix. MarketBeat recorded 7 mentions for Notable Labs and 3 mentions for Onconetix. Notable Labs' average media sentiment score of 0.96 beat Onconetix's score of 0.54 indicating that Onconetix is being referred to more favorably in the media.
Notable Labs has a consensus price target of $7.00, suggesting a potential upside of 573.08%. Given Onconetix's higher possible upside, analysts plainly believe Notable Labs is more favorable than Onconetix.
Notable Labs has higher revenue and earnings than Onconetix. Notable Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Summary
Notable Labs beats Onconetix on 9 of the 15 factors compared between the two stocks.
Get Notable Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTBL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTBL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Notable Labs Competitors List
Related Companies and Tools
